Foresite Capital is an equity firm in the healthcare business based in San Francisco serving both the private and public markets. The inclusion of Dr. Molly He as a venture partner will see the company increase regarding production, sales, and opening of satellite offices. Jim Tananbaum is excited because she has vast experience and knowledge in pharmaceutical, genomic research and development. Jim believes she will diversify and expand the Foresite Capital’s portfolio.
According to drewaltizer.com, in the Past Dr. Molly He has been the executive director at Illumina. She was in charge of scientific research on protein reagent innovation and improvement. Elsewhere, she has headed the Protein Sciences Department at Pacific Biosciences and pharmaceutical industry. In the latter, she was overseeing studies on the structural-based design of antibody and drug development for immune diseases and dreaded cancer.
She has dedicated a lot of her time in research and successfully authored approximated 20 papers and 20 patent applications and issued patents. All her publications are based on personalized medicine or genome sequencing. Molly He studied Biochemistry at Nankai University and has a Ph.D. in Protein Biophysics form the University of California. Not only is Foresite Capital and Jim Tananbaum excited of the addition, but she is also. She reportedly said that she is humbled to join such a dynamic team that will see a breakthrough in drug discovery and clinical research.
About Jim Tananbaum
Jim Tananbaum is the founder, Chief Executive Officer and Managing Director of the 25-year-old Foresite Capital that has been exploiting strategic, operational and financial opportunities in the healthcare industry. As the liaison of the group, he has been vibrant in implementing organizational investment strategy and structure. Jim Tananbaum has grown Foresite Capital into a Franchise business and invested in the pharmaceuticals such as Amira, Jazz, and Amerigroup among others.
Tananbaum is an alumnus of Harvard School; a medical degree and an M.B.A from the Business School and Yale University a B.S and B.S.E.E. In recent new from INC42, Jim Tananbaum made it to the Forbes’ Midas List of 2017. He has co-founded GelTex Pharmaceuticals, Theravance Inc and Prospect Venture Partners II and III. Jim Tanabaum is affiliated with TrueBridge Capital Partners through Foresite Capital.